Topping the spate of high-dollar collaborations announced Monday, Seattle Genetics Inc. signed Genentech Inc. to a potential $860M partnership to develop SGN-40, a monoclonal antibody in early clinical testing in hematologic cancers. (BioWorld Today)

Pharmacopeia Drug Discovery Inc. could receive up to $189 million in a deal with Wyeth Pharmaceuticals to develop compounds inhibiting JAK3, a target that has gained interest over the last few months in the area of inflammatory disease. (BioWorld Today)

Pharmacopeia Drug Discovery Inc. could receive up to $189 million in a deal with Wyeth Pharmaceuticals to develop compounds inhibiting JAK3, a target that has gained interest over the last few months in the area of inflammatory disease. (BioWorld Today)